Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory, with Excess of Blasts 2Wilms Tumor 1Uveal Melanoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Primary Malignant Peripheral Nerve Sheath Tumors 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oligodendroglioma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Hepatoblastoma 1Gliosarcoma 1Glioma 1Glioblastoma 1GATA2 Deficiency 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1Anemia, Refractory 1

Interventions

Radiosurgery 23Temozolomide 14Magnetic Resonance Spectroscopy 14pembrolizumab 11Bevacizumab 11Nivolumab 10Ipilimumab 8Specimen Handling 6Memantine 6abemaciclib 5Radiotherapy 5Mental Status and Dementia Tests 5Blood Specimen Collection 5Radiation 4entrectinib 3Surveys and Questionnaires 3Sodium Chloride 3Saline Solution 3Receptors, Interleukin-8B 3Proton Therapy 3Lomustine 3trastuzumab deruxtecan 2trametinib 2pertuzumab 2osimertinib 2lenvatinib 2fluciclovine F-18 2contrast agent BR1 2atezolizumab 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × Vorinostat × 90 days × Clear all
NCT00268385 2026-05-07

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

National Cancer Institute (NCI)

Phase 1 Active not recruiting
83 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡